[An endogenous dithiol with antioxidant properties: alpha-lipoic acid, potential uses in cardiovascular diseases].
Alpha-Lipoic acid (ALA) is a natural compound, chemically named 1,2-dithiolane-3-pentanoic acid, also referred to as thioctic acid. In humans, ALA is synthetized by the liver and other tissues with high metabolic activity: heart, kidney. ALA is both water and fat soluble and therefore, is widely distributed in both cellular membranes and cytosol. Recently, a greater deal of attention has been given to antioxidant function for ALA and its reduced formed: dihydrolipoic acid (DHLA). ALA scavenges hydroxyl radicals, hypochlorous acid and singlet oxygen. It may also exert antioxidant effects in biological systems through transitional metal chelation. Dihydrolipoic acid has been shown to have antioxidant but also pro-oxidant properties in systems in which hydroxyl radical was generated. ALA/DHLA ratio has the capacity to recycle endogenous antioxidants such as vitamin E. A number of experimental as well as clinical studies point to the usefulness of ALA as a therapeutic agent for such diverse conditions as diabetes, atherosclerosis, insulin resistance, neuropathy, neurodegenerative diseases and ischemia-reperfusion injury. ALA represents a potential agent on the vascular endothelium, recording to ALA/DHLA redox couple is one of the most powerful biological antioxidant systems.
Département de pharmacologie, physiologie et physiopathologie, faculté de pharmacie, université de médecine et pharmacie Iuliu Hatieganu, 41, Victor-Babes, Cluj-Napoca, Roumanie. stelianaghibu@yahoo.com
S
S
Ghibu
C
C
Richard
S
S
Delemasure
C
C
Vergely
C
C
Mogosan
A
A
Muresan
D015126:8,11,14-Eicosatrienoic Acid; D032761:Animal Experimentation; D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy; D004730:Endothelium, Vascular / Q000187:drug effects; D016166:Free Radical Scavengers; D006801:Humans; D017665:Hydroxyl Radical; D007333:Insulin Resistance; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D010084:Oxidation-Reduction; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D008063:Thioctic Acid / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D014050:Toluene / Q000031:analogs & derivatives*; D014803:Vitamin B Complex / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D000975:Antioxidants; D016166:Free Radical Scavengers; D014803:Vitamin B Complex; D017665:Hydroxyl Radical; D014050:Toluene; D008063:Thioctic Acid; D015126:8,11,14-Eicosatrienoic Acid; C004848:dithiol